2025-11-25T14:25:20.000Z · 10 months ago PharmaCyte sells Femasys stake, sees cash position rising to $20M FEMY
Nov 25, 2025, 9:15 AM EST · 10 months ago PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment FEMY
2025-09-02T13:30:08.000Z · 1 year ago PharmaCyte Biotech increases stake in TNF Pharmaceuticals by $3M
Sep 2, 2025, 9:20 AM EDT · 1 year ago PharmaCyte Biotech, Inc. Increases Stake in TNF Pharmaceuticals Around Recent License for Breakthrough Light Speed Computing Platform for Use in Cryptocurrency Applications
Aug 20, 2025, 9:15 AM EDT · 1 year ago PharmaCyte Biotech, Inc. Announces Closing of $7 Million Financing
Aug 18, 2025, 9:15 AM EDT · 1 year ago PharmaCyte Biotech, Inc. Announces $7 Million Capital Raise Led by Existing Investors
2024-05-21T13:14:03.000Z · 2 years ago MyMD Pharmaceuticals secures $7M investment from PharmaCyte Biotech
May 21, 2024, 9:00 AM EDT · 2 years ago PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease
2023-11-15T13:37:10.000Z · 2 years ago PharmaCyte Biotech makes $5M investment in Femasys to utilize cash position FEMY
Nov 15, 2023, 8:30 AM EST · 2 years ago PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women's Health Innovator Femasys, Inc. FEMY
2023-11-15T12:37:56.000Z · 2 years ago Femasys announces upfront investment of $6.85M by PharmaCyte FEMY
Oct 31, 2023, 9:15 AM EDT · 2 years ago PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology
May 11, 2023, 8:30 AM EDT · 3 years ago PharmaCyte Biotech Announces Cash Tender Offer for up to 7,750,000 Shares at $3.25 Per Share
2023-02-02T14:15:52.000Z · 3 years ago PharmaCyte Biotech announces second $10M share repurchase plan
Feb 2, 2023, 9:00 AM EST · 3 years ago PharmaCyte Biotech to Implement Second $10-Million Share Repurchase Plan
Oct 7, 2022, 9:00 AM EDT · 3 years ago PharmaCyte Biotech Board of Directors Announces Business Review Committee to Evaluate Opportunities to Optimize Shareholder Value
Aug 15, 2022, 8:30 AM EDT · 4 years ago PharmaCyte Biotech Reaches Cooperation Agreement with Iroquois Capital
Jul 28, 2022, 12:49 PM EDT · 4 years ago PharmaCyte Biotech Rebukes Iroquois' Commencement of Consent Solicitation
Jul 28, 2022, 9:00 AM EDT · 4 years ago Iroquois Files Preliminary Consent Materials to Reconstitute Board of Directors at PharmaCyte Biotech, Inc.
Jul 21, 2022, 8:30 AM EDT · 4 years ago PharmaCyte Biotech Commences First Phase of Two-Phase Pig Study
Jul 19, 2022, 8:30 AM EDT · 4 years ago PharmaCyte Biotech Reports Positive Interim Results in Malignant Ascites Mouse Model Study
Jul 11, 2022, 8:30 AM EDT · 4 years ago PharmaCyte Biotech Announces Preliminary Unaudited Financial Results for Fiscal Year 2022
Jul 11, 2022, 6:00 AM EDT · 4 years ago IROQUOIS CAPITAL COMMENCES CONSENT SOLICITATION TO RECONSTITUTE PHARMACYTE BIOTECH BOARD OF DIRECTORS
Jul 5, 2022, 3:16 PM EDT · 4 years ago IROQUOIS CAPITAL ISSUES STATEMENT IN RESPONSE TO RECENT ACTIONS BY THE PHARMACYTE BIOTECH BOARD OF DIRECTORS
Jul 5, 2022, 8:30 AM EDT · 4 years ago PharmaCyte Biotech Announces Additional Quality Control Assay and Confirms Stability of CypCap Cells
Jun 23, 2022, 9:00 AM EDT · 4 years ago IROQUOIS CAPITAL NOMINATES SLATE OF HIGHLY QUALIFIED DIRECTOR CANDIDATES FOR ELECTION AT PHARMACYTE'S 2022 ANNUAL MEETING
Jun 15, 2022, 8:30 AM EDT · 4 years ago PharmaCyte Biotech Issues Follow-Up Response to Iroquois Capital's Second Letter on June 9 and Reiterates Commitment to Increasing Shareholder Value
Jun 13, 2022, 8:30 AM EDT · 4 years ago PharmaCyte Biotech to Attend 2022 BIO International Convention in San Diego
Jun 9, 2022, 9:00 AM EDT · 4 years ago IROQUOIS CAPITAL DELIVERS OPEN LETTER TO PHARMACYTE BIOTECH BOARD OF DIRECTORS
Jun 8, 2022, 8:30 AM EDT · 4 years ago PharmaCyte Biotech Issues Response to Iroquois Capital Letter and Announces Additional Steps to Increase Shareholder Value
Jun 2, 2022, 9:00 AM EDT · 4 years ago PharmaCyte Biotech to Implement $10-Million Share Repurchase Program
May 23, 2022, 9:00 AM EDT · 4 years ago PharmaCyte Biotech Initiates Studies to Confirm Its Pancreatic Cancer Therapy Can Treat Malignant Ascites
May 11, 2022, 9:00 AM EDT · 4 years ago Iroquois Capital Delivers Open Letter to PharmaCyte Biotech Board of Directors
Apr 27, 2022, 9:00 AM EDT · 4 years ago PharmaCyte Biotech to Attend 15th International Conference on Advanced Technologies and Treatments for Diabetes
Apr 19, 2022, 9:00 AM EDT · 4 years ago PharmaCyte Biotech Announces More Positive Tests Results for Its Pancreatic Cancer Clinical Trial Product Candidate to Satisfy FDA Requirements
Apr 13, 2022, 9:00 AM EDT · 4 years ago PharmaCyte Biotech to Accelerate Preparations for Start of Pancreatic Cancer Clinical Trial
Apr 5, 2022, 9:00 AM EDT · 4 years ago PharmaCyte Biotech Appoints Dr. Matthias Löhr to Board of Directors
Mar 22, 2022, 9:00 AM EDT · 4 years ago PharmaCyte Biotech Successfully Completes 24-Month Stability Study of Its Clinical Trial Product Candidate
Mar 16, 2022, 9:00 AM EDT · 4 years ago PharmaCyte Biotech Reports Third Quarter Financial Results and Operational Highlights
Feb 22, 2022, 9:00 AM EST · 4 years ago PharmaCyte Biotech Announces Genetic Stability of Cytochrome P450 Gene and Site of Integration
Feb 14, 2022, 9:00 AM EST · 4 years ago PharmaCyte Biotech Updates Status of Investigational New Drug Application to FDA
Jan 6, 2022, 9:00 AM EST · 4 years ago PharmaCyte Biotech to Present at H.C. Wainwright BioConnect Conference
Jan 4, 2022, 9:00 AM EST · 4 years ago PharmaCyte Biotech Study Proves Capsule Material Is Not Toxic For Encapsulated Cells
Dec 28, 2021, 9:00 AM EST · 4 years ago PharmaCyte Biotech Successfully Completes 36 Month Master Cell Bank Stability Study
Dec 15, 2021, 9:00 AM EST · 4 years ago PharmaCyte Biotech Reports Second Quarter 2021 Financial Results and Operational Highlights
Dec 8, 2021, 10:16 AM EST · 4 years ago PharmaCyte Biotech Successfully Completes Cytochrome P450 Site of Integration DNA Sequencing Assay
Nov 30, 2021, 1:05 AM EST · 4 years ago PharmaCyte Biotech Launches Malignant Ascites Program with Commencement of Pivotal Preclinical Study
Nov 12, 2021, 9:00 AM EST · 4 years ago PharmaCyte Biotech Announces Cell Encapsulation Technology Material Does Not Cause Skin Irritation
Sep 27, 2021, 9:00 AM EDT · 5 years ago PharmaCyte Biotech Announces Encapsulation Material Does Not Alter Cellular DNA
Sep 21, 2021, 9:00 AM EDT · 5 years ago PharmaCyte Biotech Releases More Positive Results From FDA-Required Biocompatibility Tests
Sep 16, 2021, 9:00 AM EDT · 5 years ago PharmaCyte Biotech Announces Positive Results of Biocompatibility Study for FDA
Sep 8, 2021, 9:00 AM EDT · 5 years ago PharmaCyte Biotech to Participate in H.C. Wainwright 23rd Annual Global Investment Conference
Aug 31, 2021, 9:20 AM EDT · 5 years ago PharmaCyte Biotech Establishes 18-Month Shelf Life for Clinical Trial Product in Ongoing Stability Study
Aug 25, 2021, 9:00 AM EDT · 5 years ago PharmaCyte Biotech Expands Product Pipeline to Include Diabetes and Malignant Ascites Following $90-Million Capital Raise